Compare Davita Inc (DVA) vs Teradyne, Inc. (TER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Teradyne, Inc. — how do they compare? Davita Inc trades at $232 (market cap $15.12B), while Teradyne, Inc. trades at $363.01 (market cap $53.40B). The key difference: Teradyne, Inc. is far larger — about 3.5× Davita Inc's market cap, and Teradyne, Inc. pays a 0.15% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | TER | |
|---|---|---|
Market Cap | $15.12B | $53.40B |
Sector | Health | Technology |
52-Week High | $235.71 | $483.84 |
52-Week Low | $103.87 | $90.15 |
Enterprise Value | $27.67B | $53.23B |
Dividend Yield | — | 0.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Teradyne (TER) trades at $341.11, down 5.14% over 24 hours, with a bearish technical signal. The stock shows strong fundamentals with three consecutive quarterly earnings beats and robust profitability margins. Recent news highlights AI-driven demand boosting semiconductor testing revenue, positioning TER as a key player in robotics and AI infrastructure. Cash flow trends indicate consistent operational strength despite negative net cash flow from aggressive investing activities.
Outlook remains positive with a consensus price target of $453.60, implying 33% upside. Risks include high valuation multiples and semiconductor cycle volatility. Analyst sentiment is strongly bullish with 64.5% buy ratings, supported by expanding AI and data center markets driving long-term growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
